Skip to Content
Merck
CN
All Photos(1)

Documents

SML2841

Sigma-Aldrich

Tarenflurbil

≥98% (HPLC)

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
(R)-(−)-2-Fluoro-α-methyl-4-biphenylacetic acid, αR)-2-Fluoro-α-methyl[1,1′-biphenyl]-4-acetic acid, (-)-(R)-Flurbiprofen, (2R)-2-(3-Fluoro-4-phenylphenyl)propanoic acid, (R)-Flurbiprofen, Flurizan, R-flurbiprofen, (R)-2-Flurbiprofen, Tarenflurbil
Linear Formula:
C6H5C6H3(F)CH(CH3)CO2H
CAS Number:
51543-40-9
Molecular Weight:
244.26
MDL number:
MFCD00869714
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

C[C@@H](C(O)=O)c1ccc(c(F)c1)-c2ccccc2

InChI

1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1

InChI key

SYTBZMRGLBWNTM-SNVBAGLBSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Tarenflurbil (or R-flurbiprofen) is an R enantiomer of racemic NSAID flurbiprofen that does not inhibit either cyclooxygenase 1 (COX-1) or cyclooxygenase 2 (COX-2). Tarenflurbil potently reduces levels of beta amyloid in human cells through direct inhibition of γ-secretase.

Pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

Signal Word

Danger

Hazard Statements

H301 + H311,H317,H361d

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Oral - Repr. 2 - Skin Sens. 1B

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

T Morihara et al.
Journal of neurochemistry, 83(4), 1009-1012 (2002-11-08)
Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with reduced risk for Alzheimer's disease (AD) and selected NSAIDs racemates suppress beta-amyloid (Abeta) accumulation in vivo and Abeta42 production in vitro. Clinical use of NSAIDs for preventing or treating AD has been
Jason L Eriksen et al.
The Journal of clinical investigation, 112(3), 440-449 (2003-08-05)
Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced risk for the development of Alzheimer disease (AD). In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed for their ability to lower
Ling Rong Wong et al.
The Journal of pharmacy and pharmacology, 70(1), 59-69 (2017-10-17)
R-flurbiprofen (R-FP) was found to offer neuroprotective effects by inhibiting mitochondrial calcium overload induced by β-amyloid peptide toxicity in Alzheimer's disease (AD). However, poor brain penetration after oral administration posed a challenge to its further development for AD treatment. In

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service